Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
TScan Therapeutics, Inc. (TCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report interim data by year-end 2023 Announced FDA clearance of fourth IND for solid tumor program – TSC-200-A0201 targeting HPV16 Closed underwritten public offering with net proceeds of approximately $134.7 million Ended 2Q 2023 with cash and cash equivalents of $208.8 million, which along with $30 million proceeds from Amgen, will fund the Company into 2026 WALTHAM, Mass., Aug 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor-e..."
05/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on 5/17 at ASGCT, followed by call at 5:30 p.m. ET Appointed Barbara Klencke, M.D., to Board of Directors Ended 1Q 2023 with cash and cash equivalents of $95.6 million, which combined with Amgen partnership extends cash runway into 3Q 2024 WALTHAM, Mass., May 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell the..."
03/08/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker data by mid-year 2023 Clearance of primary IND in addition to two INDs for lead TCR-Ts supports concomitant use of multiple TCRs for solid tumor trial; initial data for most advanced TCRs anticipated by year-end 2023 Ended 2022 with cash and cash equivalents of $120.0 million, funding operations into 2Q 2024"
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid-tumor Program Targeting HPV16; TCR Advancing into IND-Enabling Activities with IND Submission Planned for Second Half of 2022 New Solid Tumor Program, TSC-204, Established Based on a TCR Targeting an HLA-C*07:02 Epitope of MAGE-A1 WALTHAM, Mass., November 10, 2021 -- TScan Therapeutics, Inc. , a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, today reported financial results for the quarter ended September 30, 2021, highlighted recent program pr..."
08/19/2021 8-K Quarterly results
Docs: "TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy